Golidocitinib

Golidocitinib is a pharmaceutical drug for the treatment of cancer. In June 2024, it was given conditional approval in China for the treatment of relapsed or refractory peripheral T-cell lymphoma.^[1]

Golidocitinib is classified as a Janus kinase inhibitor.^[2]^[3]

References

↑ "Golidocitinib: First Approval". Drugs 84 (10): 1319–1324. October 2024. doi:10.1007/s40265-024-02089-2. PMID 39298087.
↑ "Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study". The Lancet. Oncology 25 (1): 117–125. January 2024. doi:10.1016/S1470-2045(23)00589-2. PMID 38092009.
↑ "Maintenance Therapy of Golidocitinib, a JAK1 Selective Inhibitor, in Patients with Peripheral T Cell Lymphomas after First-Line Systemic Therapy: Updates of the Phase 2 Study (JACKPOT26)". Blood 144: 6368. 2024. doi:10.1182/blood-2024-211891.

0.00

(0 votes)

Original source: https://en.wikipedia.org/wiki/Golidocitinib. Read more

[1] "Golidocitinib: First Approval". Drugs 84 (10): 1319–1324. October 2024. doi:10.1007/s40265-024-02089-2. PMID 39298087.

[2] "Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study". The Lancet. Oncology 25 (1): 117–125. January 2024. doi:10.1016/S1470-2045(23)00589-2. PMID 38092009.

[3] "Maintenance Therapy of Golidocitinib, a JAK1 Selective Inhibitor, in Patients with Peripheral T Cell Lymphomas after First-Line Systemic Therapy: Updates of the Phase 2 Study (JACKPOT26)". Blood 144: 6368. 2024. doi:10.1182/blood-2024-211891.

[1]

[2]

[3]

Golidocitinib

Topic: Chemistry

References